Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of iptacopan in atypical hemolytic uremic syndrome (aHUS)
2022-502965-34-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, open-label, single-arm trial of Iptacopan in atypical hemolytic uremic syndrome (aHUS), sponsored by Novartis. Primary endpoints: Safety evaluations including adverse events and serious adverse events, Safety laboratory parameters and 2 more. Planned start Oct 2024; status: authorised.
02
Drugs
Iptacopan
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on 2022-502965-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502965-34-00.